Thrombopoietin/NN
and/CC
its/PRP$
receptor/NN
./.

Thrombopoietin/NN
(/(
TPO/NN
)/)
,/,
the/DT
primary/JJ
physiological/JJ
regulator/NN
of/IN
platelet/NN
production/NN
,/,
was/VBD
initially/RB
thought/VBN
to/TO
be/VB
a/DT
lineage-specific/JJ
factor/NN
acting/VBG
predominantly/RB
on/IN
megakaryocytopoiesis/NN
./.
=====
Detailed/JJ
studies/NNS
establish/VBP
that/IN
this/DT
cytokine/NN
mediates/VBZ
biological/JJ
effects/NNS
on/IN
a/DT
broad/JJ
spectrum/NN
of/IN
hematopoietic/JJ
progenitor/NN
cells/NNS
,/,
including/VBG
stem/NN
cells/NNS
./.
=====
TPO/NN
is/VBZ
a/DT
hormone/NN
constitutively/RB
produced/VBN
mainly/RB
by/IN
the/DT
liver/NN
and/CC
kidney/NN
./.
=====
Plasma/NN
TPO/NN
levels/NNS
are/VBP
regulated/VBN
by/IN
the/DT
platelet/NN
and/CC
megakaryocyte/NN
mass/NN
through/IN
Mpl/NN
receptor/NN
binding/NN
,/,
internalization/NN
and/CC
degradation/NN
./.
=====
The/DT
Mpl/NN
receptor/NN
is/VBZ
a/DT
member/NN
of/IN
the/DT
hematopoietin/NN
receptor/NN
superfamily/NN
lacking/VBG
intrinsic/JJ
kinase/NN
activity/NN
./.
=====
Upon/IN
ligand-induced/JJ
Mpl/NN
homodimerization/NN
,/,
the/DT
major/JJ
signaling/NN
events/NNS
for/IN
proliferation/NN
are/VBP
mediated/VBN
through/IN
the/DT
JAK2/STAT5/NN
pathway/NN
,/,
while/IN
differentiation/NN
might/MD
occur/VB
through/IN
a/DT
prolonged/JJ
activation/NN
of/IN
the/DT
MAPK/NN
pathway/NN
./.
=====
Preclinical/JJ
and/CC
clinical/JJ
studies/NNS
demonstrate/VBP
the/DT
potential/JJ
use/NN
of/IN
TPO/NN
in/IN
a/DT
variety/NN
of/IN
contexts/NNS
,/,
but/CC
it/PRP
is/VBZ
too/RB
early/JJ
to/TO
evaluate/VB
its/PRP$
benefit/NN
in/IN
reducing/VBG
platelet/NN
transfusion/NN
./.